NEW YORK (GenomeWeb News) – Galapagos subsidiary BioFocus DPI will conduct drug discovery screening and targeting studies over a one-year period for Schering-Plough, Galapagos said today.
Under the €2.8 million ($4.1 million) agreement, BioFocus will perform medicinal chemistry and studies of absorption, distribution, excretion, and pharmacokinetics for multiple Schering-Plough projects at two sites in Europe.
The company said that the agreement with the Schering-Plough Research Institute builds on an earlier drug discovery project between the companies that was agreed upon in May of this year.